Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Batlle-López, Ana
326  Ergebnisse:
Personensuche X
?
1

Features of immune mediated diseases in JAK2 (V617F)-positi..:

Álvarez-Reguera, Carmen ; Prieto-Peña, Diana ; Herrero-Morant, Alba...
European Journal of Internal Medicine.  123 (2024)  - p. 102-106 , 2024
Link: https://doi.org/10.1016/..
 
?
2

COVID-19 mRNA Based Vaccine Immune-Response Assessment in N..:

San Segundo, David ; Comins-Boo, Alejandra ; Lamadrid-Perojo, Patricia...
Vaccines.  9 (2021)  12 - p. 1429 , 2021
Link: https://doi.org/10.3390/..
 
?
3

Suppression of BCL6 function by HDAC inhibitor mediated ace..:

Cortiguera, María G. ; García-Gaipo, Lorena ; Wagner, Simon D....
Scientific Reports.  9 (2019)  1 - p. , 2019
Link: https://doi.org/10.1038/..
 
?
4

Patients with chronic lymphocytic leukemia and complex kary..:

Puiggros, Anna ; Collado, Rosa ; Calasanz, Maria José...
Oncotarget.  8 (2017)  33 - p. 54297-54303 , 2017
Link: https://doi.org/10.18632..
 
?
5

Stratifying diffuse large B-cell lymphoma patients treated ..:

Batlle-López, Ana ; de Villambrosía, Sonia González ; Francisco, Mazorra...
Oncotarget.  7 (2016)  14 - p. 18036-18049 , 2016
Link: https://doi.org/10.18632..
 
?
6

MYC as therapeutic target in leukemia and lymphoma:

Leon, Javier ; Cortiguera, Maria G ; Batlle-López, Ana..
Blood and Lymphatic Cancer: Targets and Therapy.  , 2015
Link: https://doi.org/10.2147/..
 
?
7

The epigenetic regulator CTCF modulates BCL6 in lymphoma:

Batlle-López, Ana ; Cortiguera, María G. ; Delgado, M. Dolores
Oncoscience.  2 (2015)  10 - p. 783-784 , 2015
Link: https://doi.org/10.18632..
 
?
8

Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): A..:

Pérez-Rodríguez, Almudena ; Lourés, Esther ; Rodríguez-Trillo, Ángela...
Thrombosis Research.  134 (2014)  6 - p. 1171-1175 , 2014
Link: https://doi.org/10.1016/..
 
?
9

High p27 protein levels in chronic lymphocytic leukemia are..:

Caraballo, Juan M. ; Acosta, Juan C. ; Cortés, Miguel A....
Oncotarget.  5 (2014)  13 - p. 4694-4708 , 2014
Link: https://doi.org/10.18632..
 
?
10

R-COMP versus R-CHOP as first-line therapy for diffuse larg..:

Sancho, Juan-Manuel ; Fernández-Alvarez, Rubén ; Gual-Capllonch, Francisco...
Cancer Medicine.  , 2021
Link: https://ddd.uab.cat/reco..
 
?
11

Suppression of BCL6 function by HDAC inhibitor mediated ace..:

Cortiguera, María G ; García-Gaipo, Lorena ; Wagner, Simon D...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848194/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
12

Suppression of BCL6 function by HDAC inhibitor mediated ace..:

Cortiguera, María G ; García-Gaipo, Lorena ; Wagner, Simon D...
#PLACEHOLDER_PARENT_METADATA_VALUE#.  , 2019
Link: http://hdl.handle.net/10..
 
?
13

Patients with chronic lymphocytic leukemia and complex kary..:

Puiggros, Anna ; Collado, Rosa ; Calasanz, Mª Jose...
Publisher's version.  , 2017
Link: http://hdl.handle.net/10..
 
?
14

Novel CTCF binding at a site in exon1A of BCL6 is associate..:

Batlle-López, Ana ; Cortiguera, María G ; Rosa-Garrido, Manuel...
Postprint.  , 2015
Link: http://hdl.handle.net/10..
 
?
15

MYC as therapeutic target in leukemia and lymphoma:

Cortiguera, Maria G ; Batlle-López, Ana ; Albajar, Marta..
info:eu-repo/semantics/altIdentifier/doi/10.2147/BLCTT.S60495.  , 2015
Link: https://www.dovepress.co..
 
1-15